15 results about "Indirubin" patented technology

To provide a method for treating a disease. [Solution] The present invention relates to compounds, compositions and methods for modulating skin pigmentation in a subject, and for treating or preventing UV-induced skin damage, erythema, skin aging, sunburn and hyperpigmentation. The compounds, compositions and methods of the present invention generally include compounds derived from Malassezia, including malassezin and indirubin, and / or their chemical analogues. Other uses of the compounds and compositions disclosed herein include, but are not limited to, improvement of hyperpigmentation caused by hyperpigmentation disorders, including melanocyte apoptosis, and modulation of aromatic hydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogeneration, melanosome transport, melanocyte activity and melanin concentration.

The invention discloses a platelet increasing capsule characteristic chromatogram and a construction method and application thereof, and belongs to the technical field of quality control of traditional Chinese medicine compound preparations. According to the method, 13 control components including gallic acid, catechin, paeoniflorin, forsythiaside B, benzoic acid, astragalus smicus glycoside, forsythin, arctiin, liquiritigenin, benzoyl paeoniflorin, paeonol, arctigenin and indirubin are selected, a high performance liquid chromatography-mass spectrometry technology is applied, multiple batches of preparation samples are analyzed, and the content of the components in the preparation samples is determined. And establishing a characteristic spectrum of the chemical components. Compared with a traditional method, the technology has good precision and reproducibility, the data result is accurate and reliable, meanwhile, the technology can identify the 13 components at the same time under the same chromatographic condition, the analysis efficiency is remarkably improved, synchronous monitoring of multiple effective components is achieved, and the consistency and stability of the preparation quality can be guaranteed.

This invention provides a controlled-release pharmaceutical composition containing indigo naturalis or its main active ingredient, a method for its preparation, and its application. The controlled-release pharmaceutical composition comprises microspheres, each microsphere containing the active ingredient and one or more pharmaceutically acceptable excipients. The active ingredient includes indigo naturalis, indigo, indirubin, or any combination thereof; the microspheres are coated with an enteric outer layer. The controlled-release pharmaceutical composition provided by this invention can alleviate the symptoms of inflammatory bowel diseases, especially ulcerative colitis, and can reduce or avoid the endocytosis of the active ingredient by intestinal macrophages, thereby reducing the impact on the patient's liver. It exhibits good stability, and the controlled-release pharmaceutical composition of this invention reduces side effects while maintaining therapeutic efficacy.

The invention discloses indigowoad root indigo antibacterial solid soap and a preparation method thereof. The indigowoad root indigo antibacterial solid soap is prepared from the following components in parts by mass: 5-30 parts of indigowoad root powder, 1000-1100 parts of soap base and 36-40 parts of coconut oil. The invention relates to the technical field of daily chemicals. According to the indigo indigo antibacterial solid soap and the preparation method thereof, high-purity indigo indigo powder is specially extracted, and a low-temperature cold soap making method is adopted, so that decomposition of indigo indigo and indirubin under high temperature and strong alkali is greatly avoided, and high efficiency of antibacterial and anti-inflammatory biological activity is ensured; impurities in crude indigo naturalis are removed, the risk of skin allergy and friction is reduced, the compounded soap base also makes the soap foam fine and smooth, and the skin is moist and not tight after the soap is used.

The application provides a radix isatidis granule and a preparation method thereof, which is prepared from the following components in parts by weight: radix isatidis 700 parts, sucrose 170-190 parts and dextrin 50-70 parts. The content of active ingredient (R,S)-deoxyschizandrin, the total content of uridine, guanosine and adenosine, and the content of indirubin in the prepared radix isatidis granule are significantly improved, and the quality is stable after being accelerated for 6 months.

The present invention relates to indirubin derivatives with novel heterobicyclic residues and their use as inhibitors of FLT3 (fms-like tyrosine kinase 3; FMS-like tyrosine kinase 3) and rearranged during transfection (RET) kinases. The compounds of the present invention are capable of effectively inhibiting the activity of FLT3 and RET kinases and are useful in the prevention or treatment of mutant FLT3 and mutant RET-associated diseases, in particular acute myeloid leukemia.

This invention relates to a method for producing indirubin using a co-culture system of *E. coli*, comprising the following steps: Step 1, culturing a first engineered bacterium to the late logarithmic growth stage to obtain a fermentation broth of the first engineered bacterium; Step 2, activating and culturing a second engineered bacterium to the early logarithmic growth stage, collecting and resuspending the bacterial cells to obtain a bacterial suspension of the second engineered bacterium; Step 3, inoculating the bacterial suspension of the second engineered bacterium into the fermentation broth of the first engineered bacterium, adding cysteine ​​to begin co-culture, and adding an inducer to induce expression; when co-culturing for 16-30 hours, adding indigo and / or 2-hydroxyindole; continuing co-culturing for 40-60 hours to obtain a fermentation broth containing indirubin. This invention, through a staged culture-mixed co-culture strategy, effectively solves key technical bottlenecks such as heavy metabolic burden of single strains, high toxicity of the intermediate product indole, and high production of the byproduct indigo, achieving a shake-flask level yield of 163.34 mg / L of indirubin, demonstrating good prospects for industrial application.

The present invention provides a controlled-release pharmaceutical composition containing Indigo Naturalis or its main active ingredient, and a preparation method and use thereof. The controlled-release pharmaceutical composition includes micropellets. The micropellets include an active ingredient and one or more pharmaceutically acceptable excipients, the active ingredient includes Indigo Naturalis, indigo, indirubin, or any combination thereof; wherein the micropellets have an enteric outer layer. The controlled-release pharmaceutical composition provided by the present invention can alleviate the disease condition of inflammatory bowel disease, especially ulcerative colitis, and can reduce or avoid the phagocytosis of the active ingredient by intestinal macrophages, thereby reducing the effect on the patient's liver. The composition exhibits good stability and reduces side effects while maintaining therapeutic efficacy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of indirubin in preparation of a medicine for treating polycystic ovarian syndrome. The indirubin disclosed by the invention is a natural product or an artificially synthesized product, is high in safety and small in toxic and side effects, and has a good effect of treating the polycystic ovarian syndrome.

A biosynthetic method and composition for producing indigo dyes comprising indigotin and isatin. A tryptophanase (TRP) and a flavin monooxygenase (FMO) can be produced through a transgenic organism having carrier encoded tryptophanase and flavin monooxygenase. The produced tryptophanase and flavin monooxygenase convert L-tryptophan into indigo dyes in the presence of one or more bioactive additives selected from cysteine, 2-hydroxyindole, or 2-indoxyl, and the weight ratio of indigotin to isatin in the dyes is between 1:0.1 to 1:4. The dyes have a hue of X: 0.1920 to 0.2481, Y: 0.2537 to 0.2019, Z: 0.5543 to 0.5501 in the CIE XYZ color space definition. Selectable and repeatable dyeing hues are provided.

The invention discloses a quality detection method of a strobilanthes cusia medicine. The detection method comprises the following steps: determining the content of water, total ash content, acid-insoluble ash content and extract in the strobilanthes cusia medicinal material; and performing thin-layer identification on stems and leaves of the strobilanthes cusia medicinal material. The thin-layer chromatography identification method established by the invention can simultaneously identify the thin-layer chromatography of indirubin, indigo blue and indoleglycoside, has clear and visible spots and no obvious tailing phenomenon, can better reflect the medicinal material components of the strobilanthes cusia, and can qualitatively identify the strobilanthes cusia medicinal material. And a research basis is provided for quality standard research of the strobilanthes cusia medicinal material and development of preparation products.

The present application relates to a method for preparing indirubin, comprising the steps of: forming a primary culture medium by primarily culturing an enzyme and Escherichia coli so that the enzyme is expressed in the Escherichia coli; adding isatin to the primary culture medium so as to form a secondary culture medium; secondarily culturing the secondary culture medium so as to form a tertiary culture medium; and mixing the tertiary culture medium and a solvent and performing separation so as to extract indirubin, wherein the isatin is converted into indirubin by using the Escherichia coli and the enzyme.

The invention relates to the technical field of biological medicines, in particular to application of indirubin in preparation of a medicine for treating oligoasthenospermia. The indirubin disclosed by the invention is a natural product or an artificially synthesized product, is high in safety and small in toxic and side effects, and has a good effect of treating oligoasthenospermia.

A biosynthetic method and composition for producing an Indigo dyestuff including Indigotin and Indirubin. Tryptophanase (TRP) and flavin-containing monooxygenase (FMO) are generated from a genetically-modified organism having a vector coding for tryptophanase and flavin-containing monooxygenase. The conversion of L-tryptophan to Indigo dyestuff is converted by the generated TRP and FMO in the presence of one or more bioactive additives selected from the cysteine, 2-oxindole, or 2-indoxyl to form a dyestuff having a ratio of Indigotin to Indirubin by weight between 1:0.1 to 1:4. The dyestuff has a color hue defined by CIE XYZ color space with X: 0.1920 to 0.2481, Y: 0.2537 to 0.2019, Z: 0.5543 to 0.5501. Selectable and reproduceable color hues are provided.

The invention relates to a preparation method of indirubin, and particularly discloses a preparation method of indirubin. The preparation method of the indirubin comprises the following steps: (1) collecting thallus precipitates obtained after fermentation of strains capable of producing indigo blue; (2) adding water into the thallus precipitate, stirring and resuspending, and then breaking cells at low temperature; (3) adding a solvent, adjusting the pH value, and converting under ventilation and stirring conditions; (4) if the solvent is an organic solvent, collecting liquid after conversion is finished, and concentrating and drying to obtain a product containing indirubin; if the solvent is water, solid is collected after conversion is finished, and a product containing indirubin is obtained. The brand new indirubin preparation method provided by the invention is mild in conversion condition, can realize the preparation of indirubin under the conventional normal pressure condition, is suitable for large-scale production, and has important application value.